12
Participants
Start Date
May 25, 2023
Primary Completion Date
September 30, 2025
Study Completion Date
October 31, 2025
Telitacicept
"12-17 years old: Telitacicept 2.5 mg/kg (with a maximum dose of 160 mg) subcutaneously once a week plus SOC for 12 weeks.~5-11years old: Telitacicept 3.0-3.5 mg/kg (with a maximum dose of 160 mg) subcutaneously once a week plus SOC for 12 weeks."
NOT_YET_RECRUITING
Children's Hospital of Capital Institute of Pediatrics, Beijing
NOT_YET_RECRUITING
Peking Union Medical College Hospital, Beijing
NOT_YET_RECRUITING
Children's Hospital of Chongqing Medical University, Chongqing
NOT_YET_RECRUITING
Henan Children's Hospital, Zhengzhou
RECRUITING
Hunan Children's Hospital, Changsha
NOT_YET_RECRUITING
Nanjing Children's Hospital, Nanjing
NOT_YET_RECRUITING
The First Hospital of Jilin University, Changchun
NOT_YET_RECRUITING
Xi'an Children's Hospital, Xi'an
NOT_YET_RECRUITING
Children's Hospital of Fudan University, Shanghai
RECRUITING
Chengdu Women's & Children's Central Hospital, Chengdu
RECRUITING
Children's Hospital of Zhejiang University School of Medicine, Hangzhou
RECRUITING
The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou
RemeGen Co., Ltd.
INDUSTRY